Skip to main navigation Skip to search Skip to main content

A 52-week multi-center, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO)

Project: Research

Project Details

StatusActive
Effective start/end date23/09/26 → 22/09/28

Keywords

  • clinical trials
  • CLOU064R12301
  • remibrutinib
  • chronic pruritus
  • CPUO
  • chronic pruritus of unknown origin

Clinical Trial Phase

  • Phase III (a & b)